Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
Federal Trade Commission
Farmers Insurance
Chinese Patent Office
UBS
Argus Health
AstraZeneca
QuintilesIMS
Boehringer Ingelheim

Generated: October 17, 2017

DrugPatentWatch Database Preview

Eisai Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?

EISAI INC has seventeen approved drugs.

There are thirty-two US patents protecting EISAI INC drugs and there have been two Paragraph IV challenges on EISAI INC drugs in the past three years.

There are four hundred and eighty-nine patent family members on EISAI INC drugs in forty-eight countries and forty-six supplementary protection certificates in fifteen countries.

Summary for Applicant: Eisai Inc

International Patents:489
US Patents:32
Tradenames:13
Ingredients:11
NDAs:17
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-002Nov 25, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
ACIPHEX
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-001May 29, 2002► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
ARICEPT ODT
donepezil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004► Subscribe► Subscribe
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL022568-001Jul 23, 2010► Subscribe► Subscribe
Eisai Inc
ARICEPT
donepezil hydrochloride
TABLET;ORAL020690-002Nov 25, 1996► Subscribe► Subscribe
Eisai Inc
ACIPHEX
rabeprazole sodium
TABLET, DELAYED RELEASE;ORAL020973-001May 29, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for EISAI INC drugs

Drugname Dosage Strength Tradename Submissiondate
lorcaserin hydrochloride
Extended-release Tablets20 mg
BELVIQ XR
12/13/2016
perampanel
Tablets2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg
FYCOMPA
10/24/2016
rufinamide
Oral Suspension40 mg/mL
BANZEL
6/16/2014
donepezil hydrochloride
Tablets23 mg
ARICEPT
7/9/2013
rufinamide
Tablets100 mg, 200 mg and 400 mg
BANZEL
11/14/2012
donepezil hydrochloride
Orally Disintegrating Tablets5 mg and 10 mg
ARICEPT ODT
6/30/2010

Premature patent expirations for EISAI INC

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Eisai Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,954Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
7,939,5491,2-dihydropyridine compounds, manufacturing method thereof and use thereof► Subscribe
8,993,7505HT.sub.2C receptor modulators► Subscribe
5,968,989 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
8,404,675Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases► Subscribe
6,365,759 Intermediate compounds for preparing macrocylcic analogs► Subscribe
7,612,092Nitrogen-containing aromatic derivatives► Subscribe
6,653,341 Methods and compositions for use in treating cancer► Subscribe
8,846,9065HT.sub.2C receptor modulators► Subscribe
8,304,548Method for producing 1, 2-dihydropyridine-2-one compound► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eisai Inc Drugs

Country Document Number Estimated Expiration
Japan2009001584► Subscribe
Hong Kong1035534► Subscribe
China1308310► Subscribe
Norway339110► Subscribe
Poland347211► Subscribe
South Africa200605226► Subscribe
South Korea20070028459► Subscribe
Cyprus1111516► Subscribe
Germany69233768► Subscribe
Australia6272301► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eisai Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00566Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723
00493Netherlands► SubscribePRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
0Finland► Subscribe
2015000083Germany► SubscribePRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
0566Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C/GB97/023United Kingdom► SubscribePRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
1 5023-2015Slovakia► SubscribePRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601
90021-4Sweden► SubscribePRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG. NO/DATE: EU/1/11/678/001-002 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
McKinsey
Argus Health
US Army
UBS
Chubb
Fish and Richardson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot